A phase Ib/II trial of the first-in-class anti-CXCR4 antibody ulocuplumab in combination with lenalidomide or bortezomib plus dexamethasone in relapsed multiple myeloma
- Irene M. Ghobrial*
- , Chia Jen Liu
- , Robert A. Redd
- , Raymond P. Perez
- , Rachid Baz
- , Oksana Zavidij
- , Romanos Sklavenitis-Pistofidis
- , Paul G. Richardson
- , Kenneth C. Anderson
- , Jacob Laubach
- , Patrick Henrick
- , Alexandra Savell
- , Kaitlen Reyes
- , Kalvis Hornburg
- , Stacey Chuma
- , Peter Sabbatini
- , Michael D. Robbins
- , Pamela S. Becker
*此作品的通信作者
研究成果: Article › 同行評審
97
引文
斯高帕斯（Scopus）